DOD Tuberous Sclerosis Complex Idea Development Award by DOD

Opportunity ID: 44816

General Information

Document Type: Grants Notice
Funding Opportunity Number: W81XWH-09-TSCRP-IDA
Funding Opportunity Title: DOD Tuberous Sclerosis Complex Idea Development Award
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 4
Assistance Listings: 12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Jan 20, 2009
Last Updated Date:
Original Closing Date for Applications: Apr 14, 2009
Current Closing Date for Applications: Apr 14, 2009
Archive Date: May 14, 2009
Estimated Total Program Funding: $2,700,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Dept. of the Army — USAMRAA
Description: The TSCRP Idea Development Award (IDA) mechanism was first offered in FY02. Since that time, 108 IDA applications have been received, and 25 have been recommended for funding. The IDA supports high-impact, innovative research that will drive the field forward. Important aspects of the IDA are as follows:
1. Impact: The proposed research should have a significant impact on the concepts or methods that drive the field of TSC research. The proposed research is expected to make an important and original contribution to advancing TSC research or patient care.
2. Innovation: Research deemed innovative may represent a new paradigm, challenge existing paradigms, or look at existing problems from new perspectives. Research may be innovative in study concept, research methods or technology, clinical interventions, or adaptations of existing methods or technologies. Research that represents an incremental advance on previously published work is not considered innovative.
3. Preliminary Data: Preliminary data originating from the PI, research team, or collaborator that is relevant to the proposed project are required.
DOD Tuberous Sclerosis Complex Idea Development Award 3
Clinical trials are not allowed under this award mechanism. Principal Investigators (PIs) wishing to apply for funding for a clinical trial should utilize the Clinical and Translational Research Award mechanism. See the Program Announcement for the full Funding Opportunity Description.
Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil

eReceipt HELP: 301-682-5507; help@cdmrp.org

Email:cdmrp.pa@amedd.army.mil

Version History

Version Modification Description Updated Date

Folder 44816 Full Announcement-1 -> TS09 IDA_PA FINAL 20 JAN 09.pdf

Folder 44816 Full Announcement-1 -> biosketch.pdf

Folder 44816 Full Announcement-1 -> Budget Form Reader.pdf

Packages

Agency Contact Information: PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil
eReceipt HELP: 301-682-5507; help@cdmrp.org

Email: cdmrp.pa@amedd.army.mil

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
12.420 PKG00010072 Jan 20, 2009 Apr 14, 2009 View

Package 1

Mandatory forms

44816 RR_SF424-1.1.pdf

44816 RR_PerformanceSite-1.1.pdf

44816 RR_KeyPersonExpanded-1.1.pdf


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *